Advanced BioMedical Technologies, Inc.: 10-Q filed 2012-09-19
What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2012-09-19 (fiscal Q3 2012): 16 published measures, 49 facts as tagged in accession 0001387131-12-003038.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-09-19
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001387131-12-003038 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 207,606 | USD | |
| At 2011-10-31 | 213,512 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 2,206,334 | USD | |
| At 2011-10-31 | 1,776,282 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | -1,998,728 | USD | |
| At 2011-10-31 | -1,562,770 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 43,442 | USD | |
| At 2011-10-31 | 78,781 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-02-01 to 2012-07-31 | -190,879 | USD | 182 |
| 2011-11-01 to 2012-07-31 | -550,442 | USD | 274 |
| 2002-09-25 to 2012-07-31 | -3,473,925 | USD | 3598 |
| 2011-02-01 to 2011-07-31 | -189,125 | USD | 181 |
| 2010-11-01 to 2011-07-31 | -255,743 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-07-31 | 429,556 | USD | 274 |
| 2002-09-25 to 2012-07-31 | 3,124,571 | USD | 3598 |
| 2010-11-01 to 2011-07-31 | 138,892 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-11-01 to 2012-07-31 | -49,355 | USD | 274 |
| 2002-09-25 to 2012-07-31 | -441,101 | USD | 3598 |
| 2010-11-01 to 2011-07-31 | -31,580 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 141,851 | USD | |
| At 2011-10-31 | 103,170 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 64,118 | USD | |
| At 2011-10-31 | 100,714 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 1,694,508 | USD | |
| At 2011-10-31 | 1,217,815 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-02-01 to 2012-07-31 | 160,509 | USD | 182 |
| 2011-11-01 to 2012-07-31 | 464,291 | USD | 274 |
| 2002-09-25 to 2012-07-31 | 3,461,543 | USD | 3598 |
| 2011-02-01 to 2011-07-31 | 166,790 | USD | 181 |
| 2010-11-01 to 2011-07-31 | 434,624 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-02-01 to 2012-07-31 | 43,208 | USD | 182 |
| 2011-11-01 to 2012-07-31 | 73,378 | USD | 274 |
| 2002-09-25 to 2012-07-31 | 212,145 | USD | 3598 |
| 2011-02-01 to 2011-07-31 | 7,087 | USD | 181 |
| 2010-11-01 to 2011-07-31 | 7,117 | USD | 273 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | 1,665,890 | USD | |
| At 2011-10-31 | 1,626,610 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-07-31 | -175,842 | USD | |
| At 2011-10-31 | -178,961 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-02-01 to 2012-07-31 | 110,699 | USD | 182 |
| 2011-11-01 to 2012-07-31 | 372,494 | USD | 274 |
| 2002-09-25 to 2012-07-31 | 2,963,669 | USD | 3598 |
| 2011-02-01 to 2011-07-31 | 158,392 | USD | 181 |
| 2010-11-01 to 2011-07-31 | 423,603 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-02-01 to 2012-07-31 | 6,602 | USD | 182 |
| 2011-11-01 to 2012-07-31 | 18,419 | USD | 274 |
| 2002-09-25 to 2012-07-31 | 285,729 | USD | 3598 |
| 2011-02-01 to 2011-07-31 | 1,311 | USD | 181 |
| 2010-11-01 to 2011-07-31 | 3,904 | USD | 273 |
Inspect the source
- Entity
- Advanced BioMedical Technologies, Inc. / CIK 0001385799
- Captured
- SEC response SHA-256
1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))